8-cyano-5-(4-fluoro-phenyl)-3-methyl-1,3-dihydro-2,3,4-benzothiadiazepine-2,2-dioxide | 1282510-63-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 英文名称: 8-cyano-5-(4-fluoro-phenyl)-3-methyl-1,3-dihydro-2,3,4-benzothiadiazepine-2,2-dioxide
• 英文别名: 5-(4-fluorophenyl)-3-methyl-2,2-dioxo-1H-2lambda6,3,4-benzothiadiazepine-8-carbonitrile；5-(4-fluorophenyl)-3-methyl-2,2-dioxo-1H-2λ6,3,4-benzothiadiazepine-8-carbonitrile
• CAS: 1282510-63-7
• 化学式: C₁₆H₁₂FN₃O₂S
• 分子量: 329.355
• InChiKey: AKLRXQXVFXAYRR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  23
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  81.9
• 氢给体数：
  0
• 氢受体数：
  6

文献信息

• 2,3,4-BENZOTHIADIAZEPINE-2,2-DIOXIDE DERIVATIVES
  申请人：FETTER Jozsef

  公开号：US20120252784A1

  公开（公告）日：2012-10-04

  Novel 2,3,4-benzothiadiazepines-2,2-dioxides and processes for the preparation thereof are disclosed. The compounds influence the central nervous system and may be used to treat or prevent Alzheimer's disease, Parkinson's disease or Huntington's disease, senile dementia not of the Alzheimer's type, vascular dementia, post-stroke dementia, Korsakoff's syndrome, Down's syndrome, schizophrenia, panic disorder, post-traumatic stress disorder, anxiety or depression.

  揭示了新型2,3,4-苯并噻二唑二氧化物及其制备方法。这些化合物影响中枢神经系统，可用于治疗或预防阿尔茨海默病、帕金森病或亨廷顿病、老年性非阿尔茨海默型痴呆、血管性痴呆、中风后痴呆、科萨科夫综合征、唐氏综合征、精神分裂症、恐慌症、创伤后应激障碍、焦虑或抑郁症。
• [EN] 2,3,4-BENZOTHIADIAZEPINE-2,2-DIOXIDE DERIVATIVES<br/>[FR] DÉRIVÉS DE 2,3,4-BENZOTHIADIAZÉPINE-2,2-DIOXYDE
  申请人：EGIS GYOGYSZERGYAR NYILVANOSAN MUKOEDO RESZVENYTARSAGAG

  公开号：WO2011039554A2

  公开（公告）日：2011-04-07

  The present invention relates to compounds 2,3,4-benzothiadiazepine-2,2-dioxide derivatives and enantiomers of the general Formula (I) wherein 'a' represents single or double bond, R1 and R2 represent, independently, hydrogen, halogen, cyano, alkyl, alkoxy, trifluoromethyl, or if 'a' represents single bond, R1 and R2 together form =N-S-N= group, R3 and R4 represent, independently, hydrogen, alkyl, alkenyl, cycloalkyl, aryl or aralkyl, R5 and R6 represent, independently, hydrogen, halogen, cyano, alkyl, alkoxy, trifluoromethyl and/or enantiomers and/or pharmaceutically suitable acid addition salts thereof. The invention further relates to a process for their preparation, medicaments containing said compounds and the use thereof for the treatment of disorders of the central nervous system.